Intensity-modulated radiotherapy for pituitary adenomas: The preliminary report of Cleveland Clinic experience

Journal Article · Mon Jan 01 04:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.08.039· OSTI ID:20850319

Mackley, Heath B ^[1]; Reddy, Chandana A. M.S. ^[1]; Lee, S -Y ^[2]; Harnisch, Gayle A ^[3]; Mayberg, Marc R ^[4]; Hamrahian, Amir H ^[5]; Suh, John H ^[1]

---

1. Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH (United States)
2. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI (United States)
3. Department of Radiation Oncology, Porter Adventist Hospital, Denver, CO (United States)
4. Swedish Neuroscience Institute, Swedish Hospital, Seattle, WA (United States)
5. Department of Endocrinology, Cleveland Clinic, Cleveland, OH (United States)

Purpose: Intensity-modulated radiotherapy (IMRT) is being increasingly used for the treatment of pituitary adenomas. However, there have been few published data on the short- and long-term outcomes of this treatment. This is the initial report of Cleveland Clinic's experience. Methods and Materials: Between February 1998 and December 2003, 34 patients with pituitary adenomas were treated with IMRT. A retrospective chart review was conducted for data analysis. Results: With a median follow-up of 42.5 months, the treatment has proven to be well tolerated, with performance status remaining stable in 90% of patients. Radiographic local control was 89%, and among patients with secretory tumors, 100% had a biochemical response. Only 1 patient required salvage surgery for progressive disease, giving a clinical progression free survival of 97%. The only patient who received more than 46 Gy experienced optic neuropathy 8 months after radiation. Smaller tumor volume significantly correlated with subjective improvements in nonvisual neurologic complaints (p = 0.03), and larger tumor volume significantly correlated with subjective worsening of visual symptoms (p = 0.05). New hormonal supplementation was required for 40% of patients. Younger patients were significantly more likely to require hormonal supplementation (p 0.03). Conclusions: Intensity-modulated radiation therapy is a safe and effective treatment for pituitary adenomas over the short term. Longer follow-up is necessary to determine if IMRT confers any advantage with respect to either tumor control or toxicity over conventional radiation modalities.

• OSTI ID: 20850319
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 67; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ADENOMAS
DATA ANALYSIS
PATIENTS
PERFORMANCE
RADIOTHERAPY
REVIEWS
SURGERY
SYMPTOMS
TOXICITY